Marker Therapeutics, Inc. — Director's Dealing 2015

Nov 16, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2015-11-12

Reporting Person: WILSON GLYNN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-11-12	Common Stock	A	315000	$0.605	Acquired	960457	Direct
2015-11-12	Common Stock	F	86782	$0.605	Acquired	873675	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-11-12	Employee Stock Option (Right to Buy)	$0.605	A	2000000	Acquired	2025-11-12	Common Stock (2000000)	Direct

Footnotes

F1: Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan to Dr. Wilson in connection with his employment and the execution of his employment agreement.

F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award.

F3: Represents options awarded under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of Dr. Wilson's employment agreement with the Company. One million of such shares vest immediately, the remaining 1,000,000 shares vest in 23 equal monthly installments of 41,666 shares each on the last day of each of the 23 months following the grant date, and the remaining 41,682 options vest on the last day of the 24th month. The option exercise price is the closing price on the date of the grant, On November 12, 2015.